Atomoxetine
- TRADE NAME: Strattera (Lilly)
- INDICATIONS: Attention deficit hyperactivity disorder
- CLASS: Anti-attention deficit hyperactivity disorder (anti-ADHD), Norepinephrine reuptake inhibitor
- HALF-LIFE: 5 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Albuterol, Amitriptyline, Cinacalcet, Citalopram, Delavirdine, Droperidol, Duloxetine, Levalbuterol, Levomepromazine, Linezolid, Lisdexamfetamine, MAO inhibitors, Moxifloxacin, Paroxetine Hydrochloride, Sotalol, Terbinafine, Terbutaline, Tipranavir, Venlafaxine, Viloxazine, Zuclopenthixol
PREGNANCY CATEGORY: C
SUICIDAL IDEATION IN CHILDREN AND ADOLESCENTS
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
